By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

Gilead Sciences (NASDAQ:GILD) announced Saturday that its antibody-drug conjugate Trodelvy, in combination with Merck’s (NYSE ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target.

Trodelvy, in combination with Keytruda, significantly lowers the risk of progression in triple-negative breast cancer by 35%, ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Gilead previously said the Phase 3 study in 443 patients with advanced triple-negative breast cancer whose tumors express PD-L1 - the protein targeted by drugs like Keytruda - had met its goal.